Ambid Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-05-2024
- Paid Up Capital ₹ 0.60 M
as on 26-05-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5762.36%
(FY 2022)
- Profit 80.89%
(FY 2022)
- Ebitda 173.33%
(FY 2022)
- Net Worth -4.51%
(FY 2022)
- Total Assets -9.33%
(FY 2022)
About Ambid Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Arun Kumar, Ajay Kumar, and Sonali Shekhar serve as directors at the Company.
- CIN/LLPIN
U24239BR2019PTC040614
- Company No.
040614
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ambid Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Kumar  | Director | 16-Jan-2019 | Current |
| Ajay Kumar | Director | 16-Jan-2019 | Current |
| Sonali Shekhar | Director | 16-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Ambid Pharmaceuticals.
Ambid Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 5762.36% increase. The company also saw a substantial improvement in profitability, with a 80.89% increase in profit. The company's net worth dipped by a decrease of 4.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ambid Pharmaceuticals?
Unlock access to Ambid Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kushmanda Health Care Llp
Active
7 years 8 months Arun Kumar, Ajay Kumar and 1 more are mutual person
Mahabodhi Developers Private Limited
Active 12 years 7 months Arun Kumar, Ajay Kumar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ambid Pharmaceuticals?
Unlock and access historical data on people associated with Ambid Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ambid Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ambid Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
